viernes, 28 de marzo de 2014

Announcement: Updated Guidelines on Managing Drug Interactions in the Treatment of HIV-Related Tuberculosis

Announcement: Updated Guidelines on Managing Drug Interactions in the Treatment of HIV-Related Tuberculosis

Bookmark and Share
MMWR Logo
 
MMWR Weekly
Vol. 63, No. 12
March 28, 2014
 
PDF


Announcement: Updated Guidelines on Managing Drug Interactions in the Treatment of HIV-Related Tuberculosis

Weekly

March 28, 2014 / 63(12);272


Guidelines for managing pharmacologic interactions that can result when patients receive antiretroviral drugs for treatment of human immunodeficiency virus (HIV) infection together with rifamycin antibiotics for treatment of tuberculosis (TB) have been published previously (14). Newly updated guidelines, developed by CDC in collaboration with experts from other key national and international institutions, are now available athttp://www.cdc.gov/tb/publications/guidelines/tb_hiv_drugs/default.htm.
The updated guidelines include recommendations for use of newer antiretroviral drugs, including those in new classes, such as CCR5 receptor antagonists and integrase inhibitors. The new guidelines provide additional recommendations regarding use of rifampin with antiretroviral therapy; these recommendations are critical in regions where rifabutin is unavailable. New features of the guidelines include 1) summaries of clinical experience with use of specific antiretroviral regimens during TB treatment (in addition to pharmacokinetic data), 2) a table summarizing clinical experience with key antiretroviral regimens and providing recommended regimens, and 3) sections on treatment for special populations, including persons with latent TB infection, young children, pregnant women, and patients with drug-resistant TB. The online guidelines will be updated as necessary to provide clinicians with the latest information.

References

  1. CDC. Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations. MMWR 1998;47(No. RR-20).
  2. CDC. Updated guidelines for the use of rifabutin or rifampin for the treatment and prevention of tuberculosis among HIV-infected patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors. MMWR 2000;49:185–9.
  3. CDC. Updated guidelines for the use of rifamycins for the treatment of tuberculosis among HIV-infected patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors. MMWR 2004;53:37.
  4. CDC. Updated guidelines on managing drug interactions in the treatment of HIV-related tuberculosis. MMWR 2008;57:98.

No hay comentarios:

Publicar un comentario